The marketing authorisation decisions already stipulated the obligation to submit periodic safety update reports relevant to the given medicinal product authorised through the national procedure or DCP with the Czech Republic as the reference member state (RMS) according to the approved clauses in the QRD template in a modified version. The existing practical applications will not change so far.
cz